Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype.

Hepatitis C virus (HCV) is the key causative agent of blood-borne non-A, non-B hepatitis. Though a robust humoral response is detectable inside just a few weeks of main an infection and through viral persistence, the function performed by antibodies towards HCV envelope glycoproteins in controlling viral replication continues to be unclear. We describe how human monoclonal anti-HCV E2 antibody fragments remoted from a chronically HCV-infected affected person differ sharply of their talents to neutralize an infection of HepG2 cells by a vesicular stomatitis virus pseudotype bearing HCV envelope glycoproteins. Two clones have been in a position to neutralize the pseudotype virus at a focus of 10 micro g/ml, whereas three different clones utterly lacked this exercise. These knowledge can clarify the dearth of safety and the opportunity of reinfection that happen even within the presence of a robust antiviral antibody response.